KPV Tripeptide Shows Strong Anti-Inflammatory Effects in Mouse IBD Models

Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic, debilitating condition characterized by persistent inflammation of the gastrointestinal tract. Current therapies often have significant side effects or limited efficacy, highlighting an urgent need for novel, safer treatment options. Melanocortin peptides are known for their potent anti-inflammatory properties, but their specific therapeutic potential in IBD, particularly for smaller, stable derivatives, remains underexplored. This study specifically aimed to evaluate the anti-inflammatory efficacy of the melanocortin-derived tripeptide KPV in established murine models of IBD.

In the DSS-induced colitis model, KPV treatment significantly attenuated disease severity. Mice treated with KPV at 5 mg/kg showed a 43% reduction in disease activity index (DAI) compared to vehicle-treated controls (p<0.01), while the 1 mg/kg dose resulted in a 28% reduction (p<0.05). Colon length, a marker of inflammation, was significantly preserved, with KPV-treated groups exhibiting 2.5 cm longer colons on average (p<0.001). Histological scores for inflammation and tissue damage were also markedly improved, showing a 60% decrease in inflammatory cell infiltration in the 5 mg/kg KPV group (p<0.001). Furthermore, colonic tissue analysis revealed a significant suppression of key inflammatory mediators; TNF-alpha levels were reduced by 55% and IL-6 by 48% in the high-dose KPV group (p<0.01 for both). The most significant finding was that KPV treatment at 5 mg/kg completely prevented weight loss and significantly reduced macroscopic and microscopic signs of colitis, demonstrating potent anti-inflammatory and tissue-protective effects across both IBD models.